MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tentori, L.
Right arrow Articles by Graziani, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tentori, L.
Right arrow Articles by Graziani, G.

0026-895X/97/020249-10$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 52:249-258 (1997).

Inhibition of O6-Alkylguanine DNA-Alkyltransferase or Poly(ADP-ribose) Polymerase Increases Susceptibility of Leukemic Cells to Apoptosis Induced by Temozolomide

Lucio Tentori, Laura Orlando, Pedro Miguel Lacal, Elena Benincasa, Isabella Faraoni, Enzo Bonmassar, Stefania D'Atri, and Grazia Graziani

Department of Experimental Medicine and Biochemical Sciences, University of Rome "Tor Vergata," Rome, Italy (L.T., L.O., E.B., I.F., E.B., G.G.), Istituto Dermopatico dell'Immacolata, Rome, Italy (P.M.L., E.B., S.D.), and Institute of Experimental Medicine, National Research Council, Rome, Italy (E.B.)

High levels of expression of the DNA repair enzyme O6-alkylguanine DNA-alkyltransferase (OGAT) (EC 2.1.1.63) account for tumor cell resistance to methylating agents. Previous studies suggested that methylating triazenes might have a potential role for the treatment of acute leukemias with low levels of OGAT. In the current study, we transduced the human OGAT cDNA in OGAT-deficient leukemia cell clones. OGAT-transduced cells were more resistant than their OGAT-deficient counterparts to apoptosis triggered by the methylating triazene temozolomide (TZM), as indicated by the results of flow cytometry, terminal deoxynucleotidyl transferase assay, and analysis of DNA fragmentation. Depletion of OGAT activity by O6-benzylguanine increased leukemia cell sensitivity to TZM-mediated apoptosis. Moreover, combined treatment of cells with TZM and benzamide, an inhibitor of the poly(ADP-ribose) polymerase (EC 2.4.2.30), increased the apoptosis induced by the methylating agent. These results demonstrate for the first time that methyl adducts at the O6 position of guanine, which are specifically removed by OGAT, are the principal DNA lesions responsible for the induction of apoptosis on treatment of leukemic cells with the methylating triazene TZM. This study also supports the possible use of TZM for the treatment of acute leukemias and suggests new strategies to increase the susceptibility of tumor cells to methylating triazenes in the clinic.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 JCOHome page
T. M. Horton, P. A. Thompson, S. L. Berg, P. C. Adamson, A. M. Ingle, M. E. Dolan, S. M. Delaney, M. Hedge, H. L. Weiss, M.-F. Wu, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients With Refractory or Recurrent Leukemia: A Children's Oncology Group Study
J. Clin. Oncol., November 1, 2007; 25(31): 4922 - 4928.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Rinne, D. Caldwell, and M. R. Kelley
Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells
Mol. Cancer Ther., August 1, 2004; 3(8): 955 - 967.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Tentori, C. Leonetti, M. Scarsella, G. d'Amati, M. Vergati, I. Portarena, W. Xu, V. Kalish, G. Zupi, J. Zhang, et al.
Systemic Administration of GPI 15427, a Novel Poly(ADP-Ribose) Polymerase-1 Inhibitor, Increases the Antitumor Activity of Temozolomide against Intracranial Melanoma, Glioma, Lymphoma
Clin. Cancer Res., November 1, 2003; 9(14): 5370 - 5379.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Pepponi, G. Marra, M. P. Fuggetta, S. Falcinelli, E. Pagani, E. Bonmassar, J. Jiricny, and S. D'Atri
The Effect of O6-Alkylguanine-DNA Alkyltransferase and Mismatch Repair Activities on the Sensitivity of Human Melanoma Cells to Temozolomide, 1,3-bis(2-Chloroethyl)1-nitrosourea, and Cisplatin
J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 661 - 668.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. Tentori, I. Portarena, M. Barbarino, A. Balduzzi, L. Levati, M. Vergati, A. Biroccio, B. Gold, M. L. Lombardi, and G. Graziani
Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined with Poly (ADP-Ribose) Polymerase Inhibitor
Mol. Pharmacol., January 1, 2003; 63(1): 192 - 202.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Seiter, D. Liu, T. Loughran, A. Siddiqui, P. Baskind, and T. Ahmed
Phase I Study of Temozolomide in Relapsed/Refractory Acute Leukemia
J. Clin. Oncol., August 1, 2002; 20(15): 3249 - 3253.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
H. I. Robins, S. M. Chang, M. D. Prados, W.K. A. Yung, K. Hess, D. Schiff, H. Greenberg, K. Fink, K. Nicolas, J. G. Kuhn, et al.
A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study
Neuro-oncol, April 1, 2002; 4(2): 109 - 114.
[Abstract] [PDF]

Home page
 BloodHome page
L. Tentori, C. Leonetti, M. Scarsella, G. d'Amati, I. Portarena, G. Zupi, E. Bonmassar, and G. Graziani
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site
Blood, March 15, 2002; 99(6): 2241 - 2244.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. S. Middlemas, C. F. Stewart, M. N Kirstein, C. Poquette, H. S. Friedman, P. J. Houghton, and T. P. Brent
Biochemical Correlates of Temozolomide Sensitivity in Pediatric Solid Tumor Xenograft Models
Clin. Cancer Res., March 1, 2000; 6(3): 998 - 1007.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Alvino, R. Pepponi, E. Pagani, P. M. Lacal, C. Nunziata, E. Bonmassar, and S. D'Atri
O6-Benzylguanine Enhances the In Vitro Immunotoxic Activity of Temozolomide on Natural or Antigen-Dependent Immunity
J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1292 - 1300.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
S. Edara, S. Kanugula, and A. E. Pegg
Expression of the inactive C145A mutant human O6-alkylguanine-DNA alkyltransferase in E.coli increases cell killing and mutations by N-methyl-N'-nitro-N-nitrosoguanidine
Carcinogenesis, January 1, 1999; 20(1): 103 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. D'Atri, L. Tentori, P. M. Lacal, G. Graziani, E. Pagani, E. Benincasa, G. Zambruno, E. Bonmassar, and J. Jiricny
Involvement of the Mismatch Repair System in Temozolomide-Induced Apoptosis
Mol. Pharmacol., August 1, 1998; 54(2): 334 - 341.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. Tentori, P. M. Lacal, E. Benincasa, D. Franco, I. Faraoni, E. Bonmassar, and G. Graziani
Role of Wild-Type p53 on the Antineoplastic Activity of Temozolomide Alone or Combined with Inhibitors of Poly(ADP-Ribose) Polymerase
J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 884 - 893.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics